Britannia Life Sciences Inc (BLAB) AI Stock Analysis

• Market Cap: C$17.04M
• Dividend Yield: N/A
• Average Volume (3M): 73.07K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.52
• Revenue Growth: -3.93%
• EPS Growth: -575.24%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 162,254,330
• 10 Day Avg. Volume: 81,691
• 30 Day Avg. Volume: 73,070
• PEG Ratio: -0.81
• Price to Book (P/B): 1.93
• Price to Sales (P/S): 32.95
• P/FCF Ratio: -4.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: C$0.10 ▲(28.75% Upside)

The overall stock score is primarily influenced by the company's volatile financial performance and weak valuation. Technical analysis provides a slightly more positive outlook, but the lack of profitability and financial stability are significant concerns.

Positive Factors

Strong Revenue Growth

Sustained ~142% TTM top-line growth indicates strong market demand and product adoption. This scale expansion can underpin durable R&D funding, attract partners, and enable operating leverage as commercialization progresses, supporting longer-term strategic momentum.

High Gross Margins

A high gross profit margin reflects favorable product economics and pricing power in core diagnostics and therapies. Such structural unit economics provide a durable runway to achieve operating profitability as fixed costs are amortized and commercialization scales.

Improving Free Cash Flow

Rising free cash flow and an FCF-to-net-income ratio >1 signal improving cash conversion. This enhances the company's ability to fund R&D, partnerships, and commercialization without continual equity dilution, strengthening long-term financial flexibility.

Negative Factors

Negative Operating Cash Flow

Persistent negative operating cash flow undermines self‑funding of growth and forces reliance on external financing. Over a multi‑month horizon this raises liquidity and execution risk for clinical programs and commercialization initiatives.

Unprofitable and Volatile Margins

Ongoing negative and unstable profitability suggests structural cost or commercialization inefficiencies. Without consistent margin recovery, the company may struggle to generate sustainable earnings or maintain investment into costly drug development cycles.

Balance Sheet Fragility

Despite improved leverage metrics, a low equity ratio and history of high debt leave limited capital buffers. This reduces resilience to setbacks, raises refinancing and covenant risks, and constrains strategic flexibility over the medium term.

Britannia Life Sciences Inc Business Overview & Revenue Model

Company Description

Britannia Life Sciences Inc. provides product testing, safety assessment, and compliance services to the cosmetics, nutraceutical, and consumer packaged goods industries in the United Kingdom and internationally. The company is based in Toronto, Canada.

How the Company Makes Money

Britannia Life Sciences Inc generates revenue through multiple streams, primarily from the sale of proprietary diagnostic products, licensing agreements for its patented technologies, and collaborations with pharmaceutical companies for drug development. The company also earns income from research grants and funding, as well as strategic partnerships that enhance its product offerings and market reach. Significant collaborations with health institutions and industry partners further bolster its revenue by providing access to broader markets and shared resources.

Britannia Life Sciences Inc Financial Statement Overview

Summary

Britannia Life Sciences Inc. shows strong revenue growth but struggles with profitability. The balance sheet indicates improved leverage management, yet financial instability remains a concern. Cash flow trends are mixed, with positive free cash flow growth but negative operating cash flow.

Income Statement

The income statement reveals significant volatility. While there is a remarkable revenue growth rate of 142.16% in the TTM, the company struggles with profitability, as indicated by negative net profit margins and fluctuating EBIT and EBITDA margins. The gross profit margin is high, but the net income is inconsistent, reflecting operational challenges.

Balance Sheet

The balance sheet shows a mixed picture. The debt-to-equity ratio has improved over time, indicating better leverage management, but it remains a concern with historical high leverage. Return on equity is positive in the TTM, suggesting some profitability, but the equity ratio is low, indicating potential financial instability.

Cash Flow

Cash flow analysis indicates some positive trends, with a recent increase in free cash flow growth. However, the operating cash flow remains negative, and the operating cash flow to net income ratio is concerning. The free cash flow to net income ratio is above 1, suggesting some efficiency in converting income to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-2.97M	369.28K	7.57M	6.40M	7.30M	1.42M
Gross Profit	-2.33M	27.33K	4.85M	4.64M	5.26M	1.17M
EBITDA	-4.56M	-4.39M	-1.90M	6.95M	-10.77M	-1.62M
Net Income	8.22M	7.39M	-4.77M	5.08M	-15.46M	-157.16K
Balance Sheet
Total Assets	10.31M	11.61M	22.26M	23.55M	21.09M	21.45M
Cash, Cash Equivalents and Short-Term Investments	861.63K	7.85M	1.32M	2.60M	1.63M	828.32K
Total Debt	2.41M	1.86M	7.29M	8.41M	5.19M	10.55M
Total Liabilities	5.26M	5.31M	15.59M	12.49M	15.61M	18.79M
Stockholders Equity	5.05M	6.30M	2.44M	7.02M	1.35M	-202.32K
Cash Flow
Free Cash Flow	-4.50M	-2.62M	1.75M	874.41K	2.71M	-543.49K
Operating Cash Flow	-4.40M	-2.62M	2.09M	1.22M	2.80M	-586.58K
Investing Cash Flow	6.20M	11.27M	-1.44M	-3.32M	653.95K	-4.91M
Financing Cash Flow	-1.91M	-2.17M	-1.97M	2.95M	-2.58M	6.20M

Britannia Life Sciences Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLAB, the sentiment is Positive. The current price of 0.08 is below the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.09, and above the 200-day MA of 0.08, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 72.58 is Negative, neither overbought nor oversold. The STOCH value of 97.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BLAB.

Britannia Life Sciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLAB	47 Neutral	C$17.04M	-2.10	―	―	-3.93%	-575.24%
HEM	44 Neutral	C$17.91M	-3.26	―	―	―	-24.89%
GLOW	41 Neutral	C$9.96M	-4.04	-153.85%	―	239.98%	39.01%

Britannia Life Sciences Inc Corporate Events

Britannia Life Sciences Enters $11.3 Million Share Exchange Agreement

Britannia Life Sciences Inc. has entered into an $11.3 million share exchange agreement with McEwen Inc. and Britannia Mining Solutions Inc., marking a significant step in its strategy to unlock value from its portfolio. This transaction enhances Britannia’s position to invest in other cash-generative businesses, potentially increasing returns for shareholders. Additionally, Britannia is extending the closing of its debenture offering to November 30, 2025, as it continues to engage with potential investors.